Clinical trials: Pemetrexed, open to volunteers
IMMUNOTHERAPY, Neoadjuvant Therapy
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
This study aims to evaluate the efficacy and safety of neoadjuvant camrelizumab combined with chemotherapy in resectable stage IIIA and IIIB (T3-4N2) non-small cell lung cancer (NSCLC) patients.
- Conditions
- IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma, Biomarkers / Blood
- Trial name
- NCT06241807
- Testing
- Camrelizumab Plus Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong Cancer Hospital and Institute
Non-squamous Non-small Cell Lung Cancer
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy
This study targets patients with advanced NSCLC driven with positive driver genes who have failed TKI treatment, enrolling 66-78 participants.
- Trial name
- NCT06868836
- Testing
- JS207, Pemetrexed, Carboplatin or cisplatin
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Pulpitis - Irreversible
Clinical and Radiographic Evaluation of Pulpotomy Using Neoputty MTA Versus Pulpectomy Using Metapex in Vital Primary Molars Diagnosed With Symptomatic Irreversible Pulpitis in Children Aged 4 to 9 Years.
itle: Evaluation of Pulpotomy using Neoputty MTA vs. Pulpectomy using Metapex in Children (4-9 years). Objective: Compare clinical and radiographic success of pulpotomy vs.
- Trial name
- NCT06929247
- Testing
- Pulpotomy using Neoputty Mineral Trioxide Aggregate, single visit pulpectomy using metapex
- Volunteers
- 70 people
- Sponsor
- Mohamed Nashaat Mohamed
Non-small Cell Lung Cancer
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal.
- Trial name
- NCT06731907
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 41 sites in United States, Chile and 9 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Nonsquamous Nonsmall Cell Neoplasm of Lung
Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy
Maitake is reported with immunomodulatory functions against tumor growth in terms of its unique molecular structure, β-glucan polysaccharides within 1, 6 main chain having 1, 3 branches and a 1, 3 main chain having 1, 6 branches…
- Trial name
- NCT05764928
- Testing
- BLEX 404
- Where
- Taiwan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Rgene Corporation
Non Small Cell Lung Cancer
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
The purpose of this study, known as DISCERN, is to compare two different treatments for a type of lung cancer called non-small cell lung cancer (NSCLC) that does not show a marker known as PD-L1.
- Trial name
- NCT06364917
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Alabama at Birmingham
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
A phase II, single-arm, open-label study evaluating efficacy, safety and feasibility of combined chemotherapy and pembrolizumab as first line therapy and Osimertinib as second line therapy in advanced non squamous NSCLC adult…
- Conditions
- Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation
- Trial name
- NCT06142617
- Testing
- Pembrolizumab, pemetrexed, platinum, Osimertinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Peking Union Medical College Hospital
Non-Small Cell Lung Cancer
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.
- Trial name
- NCT07256509
- Testing
- SYS6010, Osimertinib, Pemetrexed
- Volunteers
- 120 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.